Richard Uhlig
Founder and CEO
With more than 25 years of business experience focused on the design and development of innovative products across various industries, Richard’s management capabilities range from ownership of regional retail businesses to the start-up and management of major corporate divisions with domestic and international product sourcing and sales experience. Previously, he was the Chairman and Chief Executive Officer of Morgan Stanley Bank, the principal banking subsidiary of Morgan Stanley, and was the Chief Investment Officer at Merrill Lynch Bank. He held other significant posts in the financial industry and served as an Executive in Residence at Cornell University’s Johnson Graduate School of Management. Richard is a graduate of Cornell University.
Benjamin Perry
President
Benjamin’s career originates from a technical background, where he spent over ten years in the software development industry. During that time, he both led and contributed to several successful projects in the public, private, and academic sectors. Benjamin’s expertise revolves around a wide breadth of disciplines including cloud computing architecture, blockchain technology, and agile project management, where his experience spans all facets of the product development lifecycle. He strives to build both human and technical systems that are accessible to all, and scale rapidly with demand. Ben has been with Quadrant Biosciences since April 2016. Until his recent promotion to President of the company, he served as the Chief Technology Officer for both Quadrant and our subsidiary Motion Intelligence LLC. Prior to 2018, he was the Vice President of Technology at both organizations. Prior to Quadrant Biosciences, Benjamin led projects for the federal statistical system and public opinion domain. More specifically, his metadata management software was installed with in the US Census Bureau as part of an NSF grant. In addition, Benjamin ran a consulting business that provided data management expertise, and software development services. He received his master’s degree in Information Science from Cornell University.
Rita Romano
President - Quadrant Laboratories LLC
Rita has 30 years of clinical laboratory experience. Prior to joining Quadrant, she was Director of the Operations Center for Laboratory Alliance of CNY, a locally owned, independent reference laboratory. In this role, she had technical and regulatory oversight of clinical laboratory services performing over 10 million tests/year. Rita earned her Bachelor of Science in Medical Technology and her Masters of Arts in Strategic Leadership from St. Bonaventure University. She is certified by the American Society of Clinical Pathologists. Rita serves as the President of the Central New York Chapter of Clinical Laboratory Association and chair of the membership committee.
Kayla Wagner
President - ASD Diagnostic Products
Kayla’s career originates from a research background in clinical psychology, where she conducted research investigating many areas of child psychopathology, including autism spectrum disorder, ADHD and 22q11.2 deletion syndrome. More specifically, Kayla’s published research has a translational focus, with her interests surrounding early identification of autism, management of the comorbidity between autism and ADHD, and targets for intervention aimed at improving social outcomes for individuals with neurodevelopmental disorders. Kayla joined Quadrant in May 2017. Until her promotion to President of ASD Diagnostic Products in April 2021, Kayla led the development and commercialization of Clarifi ASD as VP of Product Management. This followed her role as VP of Research where she developed and led the Clinical Research Department, overseeing Quadrant’s research portfolio and grants in excess of $5 million. Kayla is an advocate for child-focused mental health; in her clinical work, she provided diagnostic and psychological counseling services focused on improving functioning and well-being for children and adolescents with autism and other psychiatric disorders. Kayla earned a BS in neuroscience and psychology and an MS in Clinical Psychology at Syracuse University.
Richard Bongo
Chief Financial Officer
Richard has over 30 years of finance experience while working at many major Wall Street firms. He most recently was a Managing Director at BNP Paribas, one of Europe’s largest banks, and has also worked at such firms as Lehman Brothers, Credit Suisse, Merrill Lynch and Bank of America. Richard’s experience spans several different disciplines in finance including structuring, trading and sales at the institutional level, where he helped to usher in several cutting edge financial investment products such as Collateralized Mortgage Obligations and Commercial Mortgage Backed Securities and Collateralized Loan Obligations. Richard began his career at Coopers & Lybrand (Pricewaterhouse Coopers) where he received his CPA. He holds degrees in both Computer Information Systems and Accounting from Kings College.
David MacLean
Chief Marketing Officer
David has more than 25 years of business, research and legal experience. He recently produced two award-winning feature and documentary films and founded an MMA website and clothing company. David was the co-owner of a mixed-martial arts promotion company and co-owner and manager of a medical-device sales distribution company. Previously, he was a litigator at the firms of LeBoeuf, Lamb, Lieby & MacRae, and Nixon Hargrave Devans & Doyle. Earlier, he was a research biologist for the Cornell University Lab of Ornithology. David earned a BS from Cornell University and a JD from the University of Buffalo Law School, where he was a member of the Law Review.
Bryan Greene
Chief Operating Officer
Bryan brings to the Quadrant Biosciences team more than 10 years of experience in medical device operations, manufacturing, validation and new-product introduction at both large multinational and start-up corporations. He has a proven track record of successfully introducing Class I, II and III products at Life Technologies (Thermo Fisher Scientific), Pall Corporation and ImClone System (Eli Lilly). Most recently, Bryan was the manufacturing and operations leader during establishment and implementation of an FDA 21CFR820 compliant system at Rheonix, a medical device start-up. He received a BS in Chemical Engineering from Clarkson University.
Nick Gianadda
Chief Technology Officer
Nick has 20 years of experience in the software development, Information Technology, and security fields. Prior to joining Quadrant, he held leadership roles managing diverse teams of project managers, developers, quality assurance testers, and support personnel. Nick’s experience in developing software in the healthcare industry includes applications for single sign-on, patient data access for providers, referral & case management tools, and quality measure calculation. Nick has a long history of building highly performant teams and coordinating successful product launches. He received a BS in Computer Science from Canisius College.
Wakaba Tessier
General Counsel
Throughout her career, Wakaba has focused on regulatory compliance and privacy issues facing healthcare providers. Prior to joining Quadrant Biosciences, Wakaba was a Partner at Husch Blackwell LLP, an AmLaw 100 law firm. While there, Wakaba focused her practice on state and federal health privacy law, federal fraud and abuse issues related to the Stark Law, the False Claims Act and the Anti-Kickback Statute, and complex issues facing pharmacies and laboratories. She also led various business development initiatives and Associate recruiting activities on behalf of Husch Blackwell. Wakaba obtained her B.A. from Wellesley College and her J.D. from Washington University in St. Louis School of Law.
Naved Ameen
Executive Vice President - Corporate Strategy
Naved Ameen has over 25 years experience working in a variety of financial roles. He began his career in investment banking at Smith Barney, advising institutions ranging from credit card issuers and state housing authorities to the RTC. A majority of his career was involved with creating, marketing and trading innovative financial products for investors of every type both domestically and internationally. He also has experience as an investor as a fixed income portfolio manager at Dillon Read and as founder and portfolio manager of Tevere Capital, a hedge fund catering to insurance companies. Naved has lead trading desks at Bank of America, Lehman Brothers and Morgan Stanley. He holds a Bachelors in Economics from The University of Pennsylvania.
Rita Tarolli Marble
Executive Vice President - Human Resources
Rita has more than 20 years of leadership experience in the field of Human Resource Management. Her areas of expertise include: recruitment & training, labor cost management, benefits design and administration and staff development. Prior to joining Quadrant Biosciences, she was most recently Director of Employer Solutions with a high growth PEO. In this role, Rita led in Business Development, HR Infrastructure design, onboarding and implementation of HR service plans for local and national organizations. She says she is most energized by making a meaningful impact for the organization and team she serves. Rita holds the certification of Senior Certified Professional from the Society for Human Resource Management and channels her knowledge and enthusiasm inter her community as a New Venture Mentor for the Tech Garden and subject matter resource for companies affiliated with the WISE Women’s Business Center for the SBDC. .
Andrew Brindle
Executive Vice President - Research & Development
Andrew brings a strong background in hardware design and development to the Quadrant Biosciences team. His career has included over 12 years in the defense industry working on sophisticated radar systems such as the DARPA FORESTER, the Army’s AN/TPQ-49, and radar antennas for drone helicopters. Andrew developed and holds patents on new technologies involving efficient heat transfer, and has a strong background in algorithm development having created algorithms for deep-sea underwater sensors and sports performance technologies. More recently, he has run his own engineering consulting business with a focus on commercial manufacturing and medical devices. Andrew received a BS in Mechanical Engineering with a minor in Mathematics from Clarkson University.
Ira Fedder, MD
Executive Vice President - Corporate Strategy
Dr. Fedder is a fellowship trained orthopedic spine surgeon practicing at the University of Maryland, St. Joseph Medical Center in Towson, Maryland. Dr Fedder is Board Certified by the ABOS as well as the ABSS and an active member of a number of professional organizations. Dr Fedder has participated in a number of clinical trials, has published widely in both the orthopedic and pharmacology literature, and has been an active lecturer speaking about the current and future use of stem cells and other biologics in orthopedics. Dr Fedder received his Doctor of Pharmacy degree from the U of Maryland School of Pharmacy in 1979. Subsequently, Dr. Fedder completed a fellowship in Clinical Pharmacology at Thomas Jefferson University School of Medicine. After teaching at Northeastern University College of Pharmacy and the Veterans Administration in Boston, Dr. Fedder then returned to the University of Maryland where he graduated from the School of Medicine in 1986. After completing his residency in Orthopedic Surgery at the University of Maryland he completed a fellowship at St Joseph Medical Center in Towson. He has practiced as an orthopedic spine surgeon since 1992.
David Levitskiy
Vice President - Research & Development
David brings a biomedical engineering background to the Quadrant Biosciences research and development team. His career began in the Syracuse Biomaterials Institute developing smart-materials for wound healing applications. Since then, David has worked on projects focused on algorithm development for motion detection, as well as applying machine learning to epigenetic technologies. He has developed predictive algorithms using high-throughput sequencing data for use in the diagnosis and treatment of neurodegenerative disorders. David received his Bachelor of Science and Master’s degrees in Biomedical Engineering from Syracuse University.
Stacy Masterson
Vice President - Quality
Stacy brings to the Quadrant Biosciences team more than 15 years of Quality experience. She began her career in the laboratory working in a quality control environment. Since then, she has had a consistent record of success in the Quality field at various companies including Bristol Myers Squibb and SafeTec of America. Her experience throughout the span of her career includes non-conformance/deviation authoring and approval, Lean Principles, technology transfers, training and development, and SOP authoring. She holds a Bachelor’s degree in Chemistry from SUNY Cortland and a Master’s degree in Military History from Norwich University.
Charles Marra
Vice President - Technology
Charles has over 15 years of experience in software development, with the majority of that time focused on healthcare-based applications. Prior to joining Quadrant, he led teams that developed cloud-based applications, focusing on the customer experience. His experience in software development includes applications that aggregated clinical data into actionable dashboards, provider single sign-on portals, and web-based clinical imaging viewers. He received a BS in Business Administration from the University at Buffalo and is an Army veteran.
Karen Canestare
Vice President - Finance and Controller
Karen has 30 years of leadership experience in corporate and operations level finance and accounting in publicly and privately held organizations, as well as start-ups. Karen’s experience spans various industries including telecommunications/wireless/media, manufacturing, financial services and QSR. Karen’s experience throughout the span of her career includes financial planning & analysis, financial reporting, merger and acquisitions, audit, treasury, key stakeholder in ERP implementations, process improvement and change management, where she has championed several change initiatives of various sizes and complexities. She has earned a certification of Leadership for Success from Dale Carnegie and has participated in various mentorship programs for Women in Technology. Karen earned her Bachelor of Science in Accounting and her Masters in Business from the Madden School of Business at Le Moyne College.
Chris Horacek
Deputy General Counsel
Chris has more than 20 years of experience as corporate counsel on matters including transactions, business development, intellectual property, and regulatory compliance. He served as Deputy General Counsel and Compliance Officer for Welch Allyn, Inc. for more than 10 years, and in that capacity managed the attorneys in the legal department who worked in the areas of transactions, intellectual property, and compliance, and also served on the executive team that managed the Quality and Regulatory departments. Chris is an adjunct professor at the Syracuse College Of Law, and teaches a section of the class on technology commercialization. He received a BS in Medicine from the University of Nebraska, and a JD, with distinction, from the University of Nebraska College Of Law.
Evdokia Anagnostou, MD
Child Neurologist and Senior Clinical Scientist at Holland Bloorview Kids Rehabilitation Hospital - Associate Professor in the Department of Pediatrics at the University of Toronto
Dr. Evdokia Anagnostou, MD, is a child neurologist and senior clinician scientist at Holland Bloorview Kids Rehabilitation Hospital; associate professor in the department of pediatrics at the University of Toronto; Assistant Director of Holland Bloorview’s Research Institute and co-lead of the Autism Research Centre (ARC). She holds a Canada Research Chair in translational therapeutics in Autism Spectrum Disorder (ASD) and the Dr. Stuart D. Sims Chair in Autism at Holland Bloorview. Dr. Anagnostou’s research focuses on translating genomic and systems biology findings into novel treatments for ASD.
Diana L. Robins, PHD
Professor and the Interim Director of the AJ Drexel Autism Institute at Drexel University
Diana L. Robins, Ph.D. (University of Connecticut, 2002) is a professor and the Interim Director of the AJ Drexel Autism Institute at Drexel University, where she leads the Research Program in Early Detection and Intervention for ASD. She also holds secondary appointments in Community Health and Prevention and Psychology. Much of her work has centered around developing, validating, and refining a widely-used screening tool for ASD, the Modified Checklist for Autism in Toddlers, or M-CHAT. She is funded by the National Institutes of Health. Dr. Robins serves as the treasurer for the International Society for Autism Research.
David Beversdorf, MD
University of Missouri faculty
Dr. Beversdorf graduated from Indiana University and completed Neurology residency at Dartmouth. After his fellowship in Behavioral Neurology at University of Florida, he joined the Ohio State University faculty. He has published on memory disorders, autism, cognitive neuroscience, fMRI, neurpsychopharmacology and drug addiction. He joined the University of Missouri (Radiology, Neurology, Psychology and the Thompson Center) to focus on autism, with particular interest in pharmacofMRI as a potential treatment marker, and gene/stress interactions in autism. Dr. Beversdorf’s work has been published in journals such as Neurology, Journal of Neurology Neuroscience and Psychiatry, Proceedings of the National Academy of Sciences of the United State of America and Lancet. He is also actively involved in the Brain Imaging Center at the University of Missouri. His research has been funded by National Institute of Neurological Diseases and Stroke, National Institute On Drug Abuse, Department of Defense, Autism Treatment Network, the Stallone Fund and the National Alliance for Autism Research. He has joined the University of Missouri in the departments of Radiology, Neurology, Psychology and the Thompson Center as the William and Nancy Thompson Endowed Chair in Radiology to focus on the field of autism, with particular interest in pharmaco-functional neuroimaging as a potential treatment marker, as well as other biomarkers for treatment, and gene/stress interactions in the development of autism.
Thomas Frazier, PhD
Professor of Psychology at John Carroll University
Dr. Frazier is a licensed clinical psychologist who received his Ph.D. from Case Western Reserve University in 2004. He joined Cleveland Clinic in 2006 and from 2013-2017 was the director of the Cleveland Clinic Center for Autism. In 2017, he was hired as the Chief Science Officer at Autism Speaks, overseeing all science and service programs before joining John Carroll University in January 2020 as a Professor of Psychology. Over the last decade, Dr. Frazier has maintained an active clinical practice and research programs focused on the evaluation and treatment of autism, ADHD, and related conditions. He has published more than 120 scientific papers and has ongoing collaborations across the US and internationally.
Kristin Sohl, MD FAAP
Associate Professor, Clinical Child Health Vice Chair for Quality Improvement, Child Health Department Advocacy Director, Child Health Department Director, ECHO Autism
Kristin Sohl, MD, FAAP is an Associate Professor of Clinical Child Health at the University of Missouri, Thompson Center for Autism and Neurodevelopmental Disorders and Vice Chair of the Child Health Department. She is a pediatrician with extensive experience in medical diagnosis, evaluation and treatment of children with a concern of autism and other neurodevelopmental disorders. Dr. Sohl is regarded as an expert in quality and process improvement for comprehensive autism diagnostic and longitudinal services. She is the site principal investigator for the Autism Intervention Research for Physical Health/Autism Treatment Network (AIRP/ATN) and serves in national leadership roles with each of these programs. She is the founder of ECHO Autism, an innovative framework to increase community capacity to care for children with autism and other developmental/behavioral concerns. The ECHO Autism program is viewed as a national model in expanding autism diagnosis and treatment to underserved and rural populations-those currently faced with the longest wait times. The ECHO Autism team has established partnerships with other children’s hospitals and autism centers in more than 15 states and 5 countries. Her research focuses on systems change to improve healthcare and also focuses on understanding underlying medical conditions in individuals with autism. Dr. Sohl is a tireless advocate for children and enjoys engaging other physicians in being a voice for children’s health. She is the President Elect of the American Academy of Pediatrics, Missouri Chapter. She completed medical school and pediatric residency at the University of Missouri.
Daniel L. Coury, MD
Professor of Pediatrics and Psychiatry in the College of Medicine at The Ohio State University
Daniel L. Coury, MD is Professor of Pediatrics and Psychiatry at the College of Medicine at The Ohio State University and in the Section of Developmental and Behavioral Pediatrics for Nationwide Children’s Hospital in Columbus, Ohio. He has served on the Sub-board on Developmental-Behavioral Pediatrics of the American Board of Pediatrics, the American Board of Psychiatry and Neurology Steering Committee for Child and Adolescent Psychiatry, and on the Executive Committee of the Council of Pediatric Subspecialties. Dr. Coury is a Past President of the Academic Pediatric Association and Past President of the Society for Developmental and Behavioral Pediatrics (SDBP). In 2000 he was honored for his special contributions to developmental-behavioral pediatrics by SDBP. He has a long history of working with the federal Maternal and Child Health Bureau (MCHB), having been a MCHB Developmental-Behavioral Pediatrics Program Director, a Leadership Education in Neurodevelopmental Disabilities (LEND) Director and Medical Director of a University Center for Excellence in Developmental Disabilities (UCEDD). He has published over 80 peer reviewed articles and participated in over 40 clinical trials of vaccines and treatments for ADHD, anxiety and autism. His current primary focus is in his role as Medical Director for the Autism Speaks Autism Treatment Network (ATN) and the HRSA MCHB funded Autism Intervention Research Network on Physical Health (AIR-P). His current research activities include work on early identification of autism, improving dental care for people with autism, promoting transition of people with autism to adult health care and other services, and improving medical care for people with autism through training of primary care providers.
Steven Hicks, MD, PhD
Assistant Professor of Academic General Pediatrics at Pennsylvania State College of Medicine in Hershey, PA
Dr. Hicks is an Assistant Professor of Academic General Pediatrics at Pennsylvania State College of Medicine in Hershey, PA. He is a physician scientist who studies the influence of genetics and the environment on pediatric diseases involving growth and neurodevelopment. More specifically, Dr. Hicks is interested in how peripheral epigenetic factors such as microRNA may be utilized to predict patient oriented outcomes in pediatric disorders of neurodevelopment (e.g. autism, concussion) and growth (e.g. annorexia nervosa, obesity). His research has been recently published in JAMA Pediatrics and the Journal of Neurotrauma.
Frank Middleton, PhD
Associate Professor in the Department of Neuroscience & Physiology, Department of Psychiatry & Behavioral Sciences and the Department of Biochemistry & Molecular Biology at SUNY Upstate Medical University
Dr. Frank Middleton is an Associate Professor in the Department of Neuroscience & Physiology, Department of Psychiatry & Behavioral Sciences and the Department of Biochemistry & Molecular Biology at SUNY Upstate Medical University. He is the founder and director of the SUNY Molecular Analysis Core facility, which specializes in next-generation sequencing analysis, and has published more than 120 peer-reviewed articles and a dozen book chapters. He is a chief section editor for Behavioral Brain Functions and Frontiers in Genetics.
Ira Fedder, MD
Fellowship trained orthopedic spine surgeon practicing at the University of Maryland
Dr. Fedder is a fellowship trained orthopedic spine surgeon practicing at the University of Maryland, St. Joseph Medical Center in Towson, Maryland. Dr Fedder is Board Certified by the ABOS as well as the ABSS and an active member of a number of professional organizations. Dr Fedder has participated in a number of clinical trials, has published widely in both the orthopedic and pharmacology literature, and has been an active lecturer speaking about the current and future use of stem cells and other biologics in orthopedics. Dr Fedder received his Doctor of Pharmacy degree from the U of Maryland School of Pharmacy in 1979. Subsequently, Dr. Fedder completed a fellowship in Clinical Pharmacology at Thomas Jefferson University School of Medicine. After teaching at Northeastern University College of Pharmacy and the Veterans Administration in Boston, Dr. Fedder then returned to the University of Maryland where he graduated from the School of Medicine in 1986. After completing his residency in Orthopedic Surgery at the University of Maryland he completed a fellowship at St Joseph Medical Center in Towson. He has practiced as an orthopedic spine surgeon since 1992.
Andrew Rock
Co-founder of K2M Group, a medical device developer based in Leesburg, Va
Mr. Rock earned a reputation as a successful serial entrepreneur in the global medical technology industry. He is co-founder of K2M Group, a medical device developer based in Leesburg, Va., which became listed as a publicly traded company on NASDAQ on May 5, 2014. While at K2M, Mr. Rock developed over 17 utility and method patents for the treatment of complex spine pathologies including scoliosis, tumor and trauma, as well as for minimally invasive implants. Before his involvement in K2M, Mr. Rock was a member of the executive management team at American Osteomedix, where he co-developed a minimally invasive approach to access and treat osteoporotic compression fractures and tumors in the thoracic spine. From 1993 to 2003, he was Chairman and CEO of Rock Surgical Associates, Inc., a distributor of Orthopedic and Neurosurgical Products in the Mid-Atlantic region. Currently, Mr. Rock is the founder and managing partner of Neuro Spine Ventures LLC, an 82-member global angel investor group. Mr. Rock is also Co-Founder and Executive Director of DP Enterprises Group Inc., which provides product development and global marketing services for med-tech companies. Mr. Rock also serves on the Board of Directors for several corporations, including Quadrant Biosciences, Inc. which focuses on brain health and epigenetics diagnostics; Minneapolis-based St Teresa Medical Inc., a developer of nanotechnology-based hemostatic and dural sealants; Connecticut based Woven Orthopedics, LLC which specializes in fixation and osteoporotic and osteopenic. He is on the board of advisors for Indianapolis-based Recovery Force, LLC, and a pioneer in wearable technology for the medical, sports and defense industry sectors Mr. Rock graduated from Linsly and West Virginia University.
Mary Ann Tyszko
Chair of the Greater Syracuse Chamber of Commerce Board of Directors, and a Member of Le Moyne College Management Division Advisory Board
Ms. Tyszko has over 30 years of experience in program planning, execution, and management. She served as Chief Executive Officer and President of SRCTec Inc. from its inception until August 2010. Prior to that, she served as an Executive Vice President, Operations for SRC, responsible for the day-to-day management and financial results of SRC’s four business centers. Ms. Tyszko is Chair of the Greater Syracuse Chamber of Commerce Board of Directors, and a Member of Le Moyne College Management Division Advisory Board. She is a National Director of the Association of Old Crows (AOC) and a Member of the Armed Forces Communications and Electronics Association (AFCEA), the Association of the United States Army (AUSA), the United States Field Artillery Association (USFAA), and the National Association of Corporate Directors (NACD). Ms Tyszko also has been Corporate Chair of Go Red for Women, American Heart Association, as well as a Board Member of Manufacturers Association of Central New York (MACNY). She received her MBA and MS in Computer Science from Syracuse University and a BS in Biology from Le Moyne College.
Richard Uhlig
Founder and CEO
With more than 25 years of business experience focused on the design and development of innovative products across various industries, Richard’s management capabilities range from ownership of regional retail businesses to the start-up and management of major corporate divisions with domestic and international product sourcing and sales experience. Previously, he was the Chairman and Chief Executive Officer of Morgan Stanley Bank, the principal banking subsidiary of Morgan Stanley, and was the Chief Investment Officer at Merrill Lynch Bank. He held other significant posts in the financial industry and served as an Executive in Residence at Cornell University’s Johnson Graduate School of Management. Richard is a graduate of Cornell University.
Peter Cohen
Chairman of the Board of Andover National Corporation and PolarityTE
Mr. Cohen is currently Chairman of two public companies, Andover National Corporation and PolarityTE. From 1994 through 2018 he was Chairman and Chief Executive Officer of Cowen Inc. a well-known financial services firm with a strong reputation in biotech and life sciences and its predecessor, Ramius Capital Group which was founded by Mr. Cohen. From November 1992 to May 1994, Mr. Cohen was Vice Chairman and Director of Republic New York Corporation, as well as Chairman of Republic’s subsidiary, Republic New York Securities Corporation. Earlier, he was Chairman of the Board and Chief Executive Officer of Shearson Lehman Brothers from 1983 to 1990. From 1971 to 1983 he served in different capacities at Shearson including Chief Administrative Officer, Chief Financial Officer, President and Chief Operating Officer. Over his career, Mr. Cohen has served on a number of corporate, industry and philanthropic boards, including the New York Stock Exchange, The Federal Reserve International Capital Markets Advisory Committee, The Depository Trust Company, The American Express Company, Olivetti SpA, Telecom Italia SpA, and Kroll Inc. He was a Trustee of Mount Sinai Medical Center and today is Vice Chairman and Lead Directory of the Board of Directors of Scientific Games Corporation. Mr. Cohen received a Bachelor of Science from The Ohio State University in 1968 and his Masters of Business Administration from Columbia University in 1969.
James Croke
General Counsel
Jim was previously a structured finance/banking partner at Chapman & Cutler, Orrick, Herrington, Cadwalader and Hunton & Williams. Throughout his career, he served as counsel to underwriters and issuers in U.S. and global public offerings and private placements. Jim has been a member of the board of directors of the American Securitization Forum and a faculty member of the Practicing Law Institute. He has written and lectured on a variety of topics regarding legal and regulatory issues and annually served as a guest lecturer regarding U.S. corporate and finance law at The Universidad Panamericana in Guadalajara, Mexico. Jim practiced U.S. law in London from 1999 – 2004, as the head of Cadwalader, Wickersham & Taft LLP’s London capital markets department. Jim earned his undergraduate degree in Mathematics from the University of Kentucky and his J.D. degree from the University of Notre Dame Law School.
Richard Bongo
Chief Financial Officer
Mr. Bongo has over 30 years of finance experience while working at many major Wall Street firms. He is most recently was a Managing Director at BNP Paribas, one of Europe’s largest banks, and has also worked at such firms as Lehman Brothers, Credit Suisse, Merrill Lynch and Bank of America. Mr. Bongo’s experience spans several different disciplines in structured finance including structuring, trading and sales at the institutional level, where he helped to usher in several cutting edge financial investment products such as Collateralized Mortgage Obligations and Commercial Mortgage Backed Securities and Collateralized Loan Obligations. Mr. Bongo began his career at Coopers & Lybrand (Pricewaterhouse Coopers) where he received his CPA. He holds degrees in both Computer Information Systems and Accounting from Kings College.